Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Autoimmune, and Metabolic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAP4K2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | MAP4K2 Kinase Domain (1-304 aa). High purity (>95%), ATP-binding site intact, Sequence Verified. | View MAP4K2 Products |
| Full-Length Protein | MAP4K2 Full-Length (1-838 aa). HEK293 Expressed, Theoretical MW 95 kDa, Endotoxin <1 EU/µg. | View MAP4K2 Products |
| Resistance Mutant | MAP4K2 Gatekeeper Mutants. For selectivity and resistance profiling. | View MAP4K2 Products |
| Gene Delivery | MAP4K2 Promise-ORF / Lentivirus. Full-length ORF for stable overexpression cell lines in kinase inhibitor screening. | View MAP4K2 Products |
| Benchmark Ab | Anti-MAP4K2 Recombinant Antibody (Total & Phospho-specific). Sequence-defined positive control for Western/IF validation. | View MAP4K2 Products |
| Benchmark Inhibitor | MAP4K2 Reference Inhibitor Panel. ATP-competitive controls for assay validation. | View MAP4K2 Products |
| Validator | MAP4K2 siRNA Set (3 targets + 1 control). For knockdown verification and specificity checks. | View MAP4K2 Products |
| Related Target: MAP4K1 | MAP4K1 (HPK1) Kinase Domain. Critical selectivity counter-screen (78% homology). | View MAP4K1 Products |
| Related Target: MAP4K3 | MAP4K3 (GLK) Kinase Domain. Selectivity panel member, germinal center kinase. | View MAP4K3 Products |
| Related Target: MAP4K4 | MAP4K4 (HGK/Nck-interacting kinase). Off-target liability assessment. | View MAP4K4 Products |
| Related Target: MAPK8 | MAPK8 (JNK1). Downstream effector kinase in the MAP4K2 signaling cascade. | View MAPK8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (MAP4K1/3/4/5/6/7) | Ortholog Panel: MAP4K1/2/3/4/5 Kinase Domains, Sequence Verified by Mass Spec, >95% purity |
| Drug Resistance Mutations | Mutant MAP4K2 Recombinant Proteins (Gatekeeper & Activation Loop variants); Sequence Verified |
| Pan-Kinase Cross-Reactivity | Homolog panel proteins strictly verified by mass spec for rigorous selectivity profiling |
| Active vs Inactive Conformation Assays | Unphosphorylated (basal) and Auto-phosphorylated (active) versions available |
| Cellular Target Engagement | Lentivirus for stable MAP4K2 overexpression in Jurkat/Primary T-cells; Phospho-JNK readout compatible |
| PROTAC Ternary Complex Formation | Full-length MAP4K2 with intact C-terminus for E3 ligase recruitment studies |
| Lack of Controls | Anti-MAP4K2 Total/Phospho Antibodies + Reference Inhibitors included for baseline standardization |
| False Positives / Target Confirmation | Validated siRNA included for MAP4K2 knockdown specificity checks |
Live MAP4K2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP4K2 (Germinal Center Kinase, GCK / HGK) therapeutics is advancing through preclinical and early translational stages. Historically challenged by pan-kinase off-target toxicity due to high homology with MAP4K1 (HPK1) (~78% kinase domain identity), major players are shifting focus from traditional ATP-competitive small molecules to allosteric inhibitors and targeted protein degraders (PROTACs). MAP4K2 is distinct from MAP4K1: it functions as a key node in JNK stress signaling and immune modulation, with emerging roles in metabolic disorders, inflammatory indications, and select oncology applications. The current R&D trajectory indicates a strategic shift toward family-selective inhibitors rather than pan-MAP4K approaches. As first-generation scaffolds face selectivity challenges, the field is rapidly adopting mutation-resistant scaffolds targeting the MAP4K2-specific hydrophobic back pocket, PROTAC degraders leveraging the unique C-terminal region, and allosteric inhibitors targeting the non-catalytic CNH domain. Major pharmaceutical entities are prioritizing sub-family selectivity panels as gatekeepers for lead progression, creating immediate demand for high-purity, enzymatically active MAP4K2 and its orthologs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATP-Competitive Inhibitor | Discovery-stage biopharma, Academic consortia | Solid Tumors, Autoimmune, Metabolic Syndrome | Active Kinase Assay (Need auto-phosphorylated, >95% pure MAP4K2) |
| Selective Covalent Inhibitor | Emerging Biotech | Autoimmune Diseases | Cysteine Accessibility Assay (Need full-length MAP4K2 with native cysteine pattern) |
| Allosteric (CNH Domain) | Early Discovery | Neuroinflammation, Metabolic Disorders | Domain-Specific Binding (Isolated CNH domain protein available) |
| PROTAC / Degrader | Emerging biotech platforms, Academic/Pharma | Refractory Cancers, JNK-driven oncology | Ternary Complex Formation (Need full-length protein, not just kinase domain) |
| siRNA / Antisense | Gene Therapy Companies | Autoimmune Diseases | Knockdown Validation (Need benchmark reagents and siRNA) |
| Combination Therapy (IO) | Preclinical research groups | Immuno-Oncology | Cellular JNK Pathway Readout (Need Lentivirus ORF Cell Lines) |
As the MAP4K family biology differentiates, successful programs will require rigorous counter-screening against MAP4K1 (HPK1) to avoid unintended immune activation, and against MAP4K4 to prevent metabolic liabilities. TarMart's sequence-verified ortholog panel enables definitive selectivity determination at the lead optimization stage.